AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12578771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) application during silicone intubation (SI) at 0.2 mg/ml for 2 minutes before SI
Number of subjects: 24
Study 12578771 — intervention group
Group type: COMPARATOR
Intervention: Placebo application during silicone intubation (SI)
Number of subjects: 24
Study 12578771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) application during silicone intubation (SI)
Number of subjects: 24
Study 10475361 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus immediate androgen suppression (LHRH agonist)
Number of subjects: 139
Study 10475361 — intervention group
Group type: COMPARATOR
Intervention: RT alone with hormonal manipulation at relapse
Number of subjects: 139
Study 8607742 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable performance-based assessment of balance and gait
Number of subjects: 24
Study 1939527 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 micrograms 1,25‐(OH)2D3, orally, twice per day for 6 months
Number of subjects: 98
Study 1939527 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 98
Study 6110634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam
Number of subjects: 62
Study 6110634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 31987664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day
Number of subjects: 664
Study 31987664 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 664
Study 29681185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively-Based Compassion Training (CBCT)
Number of subjects: 56
Study 29681185 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 56
Study 27206047 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic Violence Enhanced Home Visitation Program (DOVE) intervention group, n = 124
Number of subjects: 239
Study 27206047 — intervention group
Group type: EXPERIMENTAL
Intervention: DOVE treatment group
Number of subjects: 239
Study 27206047 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 239
Study 24794243 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 1·5 once a week)
Number of subjects: 595
Study 24794243 — intervention group
Group type: COMPARATOR
Intervention: No carboplatin
Number of subjects: 595
Study 24794243 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 1·5 once a week) in triple-negative breast cancer
Number of subjects: 595
Study 24794243 — intervention group
Group type: COMPARATOR
Intervention: No carboplatin in triple-negative breast cancer
Number of subjects: 595
Study 24794243 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 1·5 once a week) in HER2-positive breast cancer
Number of subjects: 595
Study 24794243 — intervention group
Group type: COMPARATOR
Intervention: No carboplatin in HER2-positive breast cancer
Number of subjects: 595
Study 24794243 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 595
Study 24794243 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 2·0 to 1·5)
Number of subjects: 595
Study 23036218 — intervention group
Group type: EXPERIMENTAL
Intervention: XR‐NTX 380 mg
Number of subjects: 250
Study 23036218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 20603424 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective videotape-based feedback intervention tailored to risk groups
Number of subjects: 0
Study 18570576 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g
Number of subjects: 672
Study 18570576 — intervention group
Group type: COMPARATOR
Intervention: Cefotetan 2 g
Number of subjects: 672
Study 15549344 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 inhibitor celecoxib add on to risperidone
Number of subjects: 0
Study 15549344 — intervention group
Group type: COMPARATOR
Intervention: Risperidone alone
Number of subjects: 0
Study 15037714 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 9
Study 15037714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 10856310 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy (OT) at 4 l/min
Number of subjects: 25
Study 10856310 — intervention group
Group type: COMPARATOR
Intervention: Air therapy (AT) at 4 l/min
Number of subjects: 25
Study 10856310 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy (OT) at baseline
Number of subjects: 25
Study 9201614 — intervention group
Group type: EXPERIMENTAL
Intervention: Pippali Rasayana (PR) administered at a dose of 1 g p.o. three times daily for 15 days
Number of subjects: 50
Study 9201614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9201614 — intervention group
Group type: EXPERIMENTAL
Intervention: Pippali Rasayana (PR)
Number of subjects: 50
Study 1284487 — intervention group
Group type: EXPERIMENTAL
Intervention: Denopamine 10 mg and Midodrine HCl 4 mg
Number of subjects: 6
Study 1284487 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not specified dosage or treatment)
Number of subjects: 6
Study 3857627 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion at 2 mg/kg of body weight per min
Number of subjects: 15
Study 31218374 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexed two-finger technique
Number of subjects: 42
Study 31218374 — intervention group
Group type: COMPARATOR
Intervention: Two-thumb technique
Number of subjects: 42
Study 31218374 — intervention group
Group type: COMPARATOR
Intervention: Two-finger technique
Number of subjects: 42
Study 30465339 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesive treatment for 10 s (adult teeth)
Number of subjects: 30
Study 30465339 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesive treatment for 20 s (adult teeth)
Number of subjects: 30
Study 30465339 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesive treatment for 30 s (adult teeth)
Number of subjects: 30
Study 30465339 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesive treatment for 10 s (youth teeth)
Number of subjects: 30
Study 30465339 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesive treatment for 20 s (youth teeth)
Number of subjects: 30
Study 30465339 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesive treatment for 30 s (youth teeth)
Number of subjects: 30
Study 27540041 — intervention group
Group type: COMPARATOR
Intervention: Usual care (educational material and support for searching)
Number of subjects: 262
Study 27540041 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on high risk prescribing (quarterly feedback on five occasions)
Number of subjects: 262
Study 27540041 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback plus behavioural change component
Number of subjects: 262
Study 24130347 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics group (AG) - treated exclusively with antibiotics for 90 days
Number of subjects: 24
Study 24130347 — intervention group
Group type: COMPARATOR
Intervention: Surgical group (SG) - underwent conservative surgery with postoperative antibiotic treatment for 10 days
Number of subjects: 24
Study 23427386 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (performed three times/week from postoperative day 7 until postoperative day 21)
Number of subjects: 80
Study 23427386 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture treatment)
Number of subjects: 80
Study 19726173 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer support intervention at the time of bronchoscopy
Number of subjects: 233
Study 19726173 — intervention group
Group type: COMPARATOR
Intervention: Brief advice (control group)
Number of subjects: 233
Study 18712641 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Impairment Questionnaire (WIQ)
Number of subjects: 105
Study 15982136 — intervention group
Group type: EXPERIMENTAL
Intervention: Various child conduct problem interventions (specifics not provided)
Number of subjects: 514
Study 12666511 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage or debridement
Number of subjects: 0
Study 12666511 — intervention group
Group type: COMPARATOR
Intervention: Placebo arthroscopic procedure
Number of subjects: 0
Study 9500747 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA aqueous nasal spray 220 microg
Number of subjects: 80
Study 9500747 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA aqueous nasal spray 440 microg
Number of subjects: 80
Study 9500747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 7544732 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex (50 mg daily for 24 weeks)
Number of subjects: 27
Study 7544732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2653971 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (415 pmol iv bolus followed by a 90 minute infusion to reach an overall dose of 62.25 pmol/kg)
Number of subjects: 8
Study 2653971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2653971 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 8
Study 338395 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine 3% cream
Number of subjects: 50
Study 338395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29783905 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg lorazepam
Number of subjects: 34
Study 29783905 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 34
Study 29783905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 27731820 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5µg/kg loading within 10 min and 0.5μg•kg‐1•h‐1 maintenance to the end of pneumoperitoneum, n=20, Group A)
Number of subjects: 40
Study 27731820 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline, n=20, Group B)
Number of subjects: 40
Study 24785342 — intervention group
Group type: EXPERIMENTAL
Intervention: Niferidil (10-30 μg/kg, intravenously, in 1-3 consecutive boluses at 15-minute intervals)
Number of subjects: 134
Study 24785342 — intervention group
Group type: EXPERIMENTAL
Intervention: Niferidil
Number of subjects: 134
Study 22563638 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 256
Study 22563638 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 256
Study 20234144 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (1.0 mg/kg) after indomethacin administration
Number of subjects: 68
Study 20234144 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo after indomethacin administration)
Number of subjects: 68
Study 18564322 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidant Personality Disorder (APD)
Number of subjects: 0
Study 18564322 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline Personality Disorder (BPD)
Number of subjects: 0
Study 18564322 — intervention group
Group type: EXPERIMENTAL
Intervention: Both APD and BPD
Number of subjects: 0
Study 18564322 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of depression
Number of subjects: 0
Study 18564322 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline and avoidant personality pathology
Number of subjects: 0
Study 15790982 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone 400 microg daily for 12 weeks
Number of subjects: 95
Study 15790982 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone 2000 microg daily for 12 weeks
Number of subjects: 95
Study 15790982 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-smokers receiving inhaled beclomethasone)
Number of subjects: 95
Study 12419410 — intervention group
Group type: EXPERIMENTAL
Intervention: Confectionery snack
Number of subjects: 21
Study 12419410 — intervention group
Group type: COMPARATOR
Intervention: Noncalorie snack
Number of subjects: 21
Study 10429835 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir administered by intravenous route (up to 600 mg)
Number of subjects: 0
Study 10429835 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir administered by oral route
Number of subjects: 0
Study 10429835 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir administered by intranasal route
Number of subjects: 0
Study 10429835 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir administered by inhaled route (nebuliser and dry powder)
Number of subjects: 0
Study 10429835 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir (all routes)
Number of subjects: 0
Study 7751495 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for depression (12 sessions)
Number of subjects: 0
Study 2196036 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vitrectomy
Number of subjects: 616
Study 2196036 — intervention group
Group type: COMPARATOR
Intervention: Deferral of vitrectomy for 1 year
Number of subjects: 616
Study 2196036 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vitrectomy in type I diabetes group
Number of subjects: 616
Study 2196036 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vitrectomy in type II diabetes group
Number of subjects: 616
Study 393053 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine, 2.5 mg twice a day
Number of subjects: 0
Study 6418666 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-H+ stimulus with workload reduction
Number of subjects: 0
Study 6418666 — intervention group
Group type: COMPARATOR
Intervention: Constant ventilation (VE) with regulated PETCO2 and PETO2
Number of subjects: 0
Study 6418666 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal clamps termination
Number of subjects: 0
Study 6418666 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing CO2
Number of subjects: 0
Study 30811844 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary alveolar bone grafting
Number of subjects: 45
Study 28991823 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin‐1 receptor antagonist
Number of subjects: 529
Study 28991823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study 27581874 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter left atrial appendage occlusion (LAAO)
Number of subjects: 0
Study 25489341 — intervention group
Group type: EXPERIMENTAL
Intervention: Rater training (brief frame-of-reference training)
Number of subjects: 242
Study 22836295 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n=60) - underwent 3 specific loads of different types, durations, and intensities
Number of subjects: 90
Study 22836295 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 90
Study 20669817 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% strontium acetate dentifrice
Number of subjects: 0
Study 20669817 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 16246656 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal misoprostol (800 mcg)
Number of subjects: 442
Study 16246656 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (800 mcg)
Number of subjects: 442
Study 11917285 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (340 mg/m2) plus RT
Number of subjects: 191
Study 11917285 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 191
Study 8110570 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane 1.5%
Number of subjects: 40
Study 8110570 — intervention group
Group type: EXPERIMENTAL
Intervention: halothane 0.75%
Number of subjects: 40
Study 8110570 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl 1 microgram kg‐1
Number of subjects: 40
Study 8110570 — intervention group
Group type: COMPARATOR
Intervention: pooled data from all subjects
Number of subjects: 40
Study 2675427 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 400 mg twice daily for two years or until death
Number of subjects: 181
Study 2675427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 341363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (200 or 300 mg every 6 hours)
Number of subjects: 55
Study 341363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31857014 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular (LV) stimulation
Number of subjects: 303
Study 27823977 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib alone
Number of subjects: 160
Study 27823977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab (200 mg, i.v. weekly) plus gefitinib (250 mg p.o. daily)
Number of subjects: 160
Study 23026548 — intervention group
Group type: EXPERIMENTAL
Intervention: BTDS 10 mcg/hour patches applied for seven days
Number of subjects: 37
Study 21876308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone and vitamin A
Number of subjects: 76
Study 21876308 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone only
Number of subjects: 76
Study 19797951 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Number of subjects: 4
Study 19797951 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4
Study 17852372 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior warning
Number of subjects: 31
Study 17852372 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting-induced fatigue
Number of subjects: 31
Study 17852372 — intervention group
Group type: COMPARATOR
Intervention: Light callisthenic exercises
Number of subjects: 31
Study 15485478 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels
Number of subjects: 0
Study 15485478 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels
Number of subjects: 0
Study 15485478 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1ra levels
Number of subjects: 0
Study 11074869 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 120
Study 8792880 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oxygen in nitrogen (group 1, n = 12)
Number of subjects: 24
Study 8792880 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen (group 2, n = 12)
Number of subjects: 24
Study 15374364 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone (45 mg twice daily orally)
Number of subjects: 102
Study 15374364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 3880997 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 0
Study 3880997 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) with diuretic treatment
Number of subjects: 0
Study 3880997 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) without diuretic treatment
Number of subjects: 0
Study 3880997 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study 31544803 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 30
Study 30140327 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced oscillation technique (FOT) with 200 mcg salbutamol by MDI
Number of subjects: 106
Study 30140327 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced oscillation technique (FOT)
Number of subjects: 106
Study 30140327 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial reversibility test using FOT
Number of subjects: 106
Study 26630309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate rich beverage (12.8 mmol nitrate)
Number of subjects: 10
Study 26630309 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (Placebo)
Number of subjects: 10
Study 25757036 — intervention group
Group type: EXPERIMENTAL
Intervention: SPORT surgical treatment
Number of subjects: 1323
Study 25757036 — intervention group
Group type: COMPARATOR
Intervention: NSQIP surgical treatment
Number of subjects: 1323
Study 23332717 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparoscopic hysterectomy (M-LPS)
Number of subjects: 68
Study 23332717 — intervention group
Group type: COMPARATOR
Intervention: Single-port hysterectomy (LESS)
Number of subjects: 68
Study 19557517 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 2449
Study 18691725 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive inurement exercises (painful stimulation) for 14 days
Number of subjects: 15
Study 18691725 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects performing sports without painful stimulation)
Number of subjects: 15
Study 18691725 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive inurement exercises
Number of subjects: 15
Study 18691725 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 16541857 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at Tongli (HT 5), Gongsun (SP 4), Neiting (ST 44), Hegu (LI 4)
Number of subjects: 74
Study 16541857 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine (VitB2, VitC)
Number of subjects: 74
Study 14666760 — intervention group
Group type: EXPERIMENTAL
Intervention: Yuantong Capsule (YTC), 1 capsule orally, 3 times a day for 2 months
Number of subjects: 83
Study 14666760 — intervention group
Group type: COMPARATOR
Intervention: Hydergine, 2 mg orally, 3 times a day for 2 months
Number of subjects: 83
Study 11190420 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglitinide analogues (repaglinide and nateglinide)
Number of subjects: 0
Study 8840849 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide 0.75 mg
Number of subjects: 12
Study 8840849 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide 0.25 mg
Number of subjects: 12
Study 8840849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6372737 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose apomorphine (0.75 mg subcutaneously)
Number of subjects: 25
Study 6372737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 29251245 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored telemonitoring
Number of subjects: 301
Study 29251245 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 301